Clinical Trials Logo

Hypersensitivity clinical trials

View clinical trials related to Hypersensitivity.

Filter by:

NCT ID: NCT03563599 Completed - Clinical trials for Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB

A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)

Start date: July 23, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase IIa, open-label, randomized study in treatment-naïve, sputum smear-positive patients with drug-sensitive pulmonary TB to assess the early bactericidal activity of telacebec (Q203).

NCT ID: NCT03563066 Completed - Dermatitis, Atopic Clinical Trials

Effect of Benralizumab in Atopic Dermatitis

Start date: September 4, 2018
Phase: Phase 2
Study type: Interventional

Atopic Dermatitis (AD), also known as eczema, is a common skin disease characterized by itchy lesions. The prevalence of AD has increased over the past few decades, with 15-30% of children and 2-10%of adults being affected. The lesions of AD patients are very inflamed, with an increased number of inflammatory cells in the skin. There are not many medications available that are fully effective and can be used long-term for treatment of atopic dermatitis. Benralizumab is a monoclonal antibody used for treatment of a type of asthma called "eosinophilic asthma". Atopic dermatitis is also associated with elevated levels of eosinophils, and we would like to determine if benralizumab is effective in patients with atopic dermatitis. This is a randomized, double-blind, parallel group, placebo-controlled study will evaluate the effect of 3 doses of a fixed 30 mg dose of benralizumab administered subcutaneously (SC) every 4 weeks to patients with moderate-to-severe atopic dermatitis, on the severity of atopic dermatitis, and the cellular inflammation of skin lesions in these patients. Anti-inflammatory properties of benralizumab when a skin flare is induced in a controlled laboratory setting, in addition to the effects of benralizumab on skin that is already inflamed will be examined.It is hypothesized that benralizumab will attenuate eosinophilic inflammation in the skin.

NCT ID: NCT03562858 Not yet recruiting - Clinical trials for Hypersensitivity Dentin

Post-operative Hyper-sensitivity Assessment After Immediate Versus Delayed Dentine Sealing in Teeth for Indirect Tooth Colored Restorations

Start date: July 2018
Phase: N/A
Study type: Interventional

PICOT elements:P: Teeth restored with indirect tooth colored restoration I: Immediate dentin sealing using universal adhesive C: Delayed dentin sealing O: Post-operative Hypersensitivity T: -Hypersensitivity assessment one week during provisionalization period and post-cementation S: Randomized Controlled Clinical Trial

NCT ID: NCT03561363 Completed - Insulin Sensitivity Clinical Trials

The Effect of 6 Weeks Saturated and Polyunsaturated High-Fat Diets on Insulin Sensitivity and Health Parameters

Start date: August 2014
Phase: N/A
Study type: Interventional

The aim of the intervention is to gain insight into the long term effect of dietary fatty acid quality on insulin sensitivity and health parameters in healthy men. Whole body and peripheral insulin sensitivity were measured, together with analyses of plasma hormones and metabolites. The plasma proteome was also analyzed. Molecular adaptations in skeletal muscle and adipose tissue were subject for investigation. Furthermore, gut microbiota population number and diversity will be analyzed from faeces samples obtained before and after the intervention.

NCT ID: NCT03557671 Completed - Cow Milk Allergy Clinical Trials

Evaluation of the Hypoallergenicity of a New Formula Based on Hydrolyzed Rice Proteins

Start date: August 23, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to show the hypoallergenicity of a new thickened rice based formula (TRHF) through a double blind placebo controlled food challenge (DBPCFC), as recommended by the American Academy of Pediatrics, in subjects with IgE-mediated CMA and in subjects with non-IgE-mediated CMA.

NCT ID: NCT03553290 Recruiting - Clinical trials for Dentinal Hypersensitivity

Therapeutic Evaluation of Lower-level Laser for Treating Dentinal Hypersensitivity

Start date: August 10, 2017
Phase: N/A
Study type: Interventional

The aim of this study was to evaluate the efficacy of low energy laser for the treatment of dentinal hypersensitivity due to periodontal therapy.

NCT ID: NCT03553251 Not yet recruiting - Hypersensitivity Clinical Trials

Protocol of Reintroduction of Beta-lactams in Children at Low Risk of Anaphylaxis.

TRO-b-lact
Start date: July 30, 2018
Phase:
Study type: Observational

The purpose of this study is to establish the rationale for the practice of performing an oral reintroduction test without previous skin tests in children at low risk of IgE-mediated reaction or drug-induced toxidermia, and to confirm the criteria for a drug reintroduction test could be performed without previous skin tests, without subsequent risk of reaction for the child. The primary endpoint will be the risk of a severe IgE-mediated or delayed hypersensitivity reaction in children who received beta-lactam drug reintroduction protocol prior to skin testing.

NCT ID: NCT03546413 Completed - Peanut Allergy Clinical Trials

Follow up of LEAP Participants and Their Families

Start date: July 5, 2018
Phase:
Study type: Observational

This prospective, cross-sectional study was designed to improve understanding of how early-life introduction of peanuts may promote the maintenance of tolerance in adolescence and will serve as an additional safety evaluation of the original nutritional intervention.

NCT ID: NCT03539705 Recruiting - Allergy and Asthma Clinical Trials

Food Allergy Registry at a Single Site

Start date: January 5, 2018
Phase:
Study type: Observational

This is a registry of participants who are interested in being screened for clinical trials at a single site.

NCT ID: NCT03539692 Recruiting - Food Allergy Clinical Trials

Prescreening Protocol to Enroll in Food Allergy Clinical Studies at a Single Site

Prescreen
Start date: June 10, 2018
Phase:
Study type: Observational

This is a protocol for prescreening of participants who would like to be in clinical studies in our Center at Stanford.